Pamplona Capital Management Acquires Pelsis from LDC
August 5, 2021
Pamplona Capital Management has acquired Pelsis, the Knaresborough-headquartered manufacturer and distributor of pest control products, from mid-market private equity firm LDC. Financial terms were not disclosed; Pelsis — which has grown to more than 600 employees and increased sales from €87m to €150m under LDC — will pursue further international expansion under Pamplona's ownership.
- Buyers
- Pamplona Capital Management
- Targets
- Pelsis
- Sellers
- LDC
- Industry
- Manufacturing
- Location
- North Yorkshire, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Harwood Capital Portfolio Company Curtis Gilmour Merges with LDC-backed Pelsis
November 14, 2018
Manufacturing
Harwood Capital’s portfolio company Curtis Gilmour has merged with Pelsis Ltd., a portfolio company of LDC, combining complementary pest-control product lines and global distribution footprints. The consolidated group will be led by Pelsis Group CEO Peter Mangion and continue to operate from existing U.S. and European facilities; financial terms were not disclosed.
-
Pelsis Group Acquires Bird-B-Gone
May 5, 2021
Manufacturing
Pelsis Group, the LDC-backed global pest control specialist, has acquired Santa Ana, California-based Bird-B-Gone, a leading manufacturer of humane bird deterrents. Bird-B-Gone will operate as a wholly owned subsidiary and remain headquartered in Santa Ana, with its employees, customers and suppliers transferring to Pelsis Group; financial terms were not disclosed.
-
Norvestor Acquires Pelias and Terminix UK from Terminix to Form Northern European Pest Control Group
May 10, 2022
Environmental Services
Norvestor VIII has signed an agreement to acquire Pelias Norsk Skadedyrkontroll AS and Terminix UK Limited from Terminix Global Holdings, Inc. The assets are being divested as a condition of Terminix’s pending merger with Rentokil Initial plc; Norvestor will become the largest shareholder in the new Northern European pest control group alongside co-investor Svein Olav Stølen, management and key employees. Pelias is headquartered in Elverum, Norway (c. NOK 240m revenue and ~210 employees in 2021) and Terminix UK is headquartered in Gloucester, England (c. GBP 19m revenue and ~370 employees in 2021); the deal is expected to close in June 2022.
-
Pamplona Capital Management Acquires Controlling Interest in Latham Pool Products from Wynnchurch Capital
January 11, 2019
Building Products
Pamplona Capital Management has acquired a controlling interest in Latham Pool Products from Wynnchurch Capital; Wynnchurch will remain a significant investor alongside management and the founding family. Headquartered in Latham, New York, Latham is a leading North American manufacturer of in-ground pools, pool components and accessories with more than 20 manufacturing facilities and distribution centers across the U.S. and Canada. Pamplona said it will provide global resources and support Latham's growth and international expansion while the existing CEO, Scott Rajeski, continues to lead the company.
-
Pelican Energy Partners Acquires Lancs Industries
January 13, 2025
Energy
Houston-based private equity firm Pelican Energy Partners has acquired Lancs Industries, an Albuquerque-based manufacturer of radiation containment and shielding solutions serving the DOE, commercial nuclear, U.S. Navy, national laboratories and pharmaceutical sectors. Pelican said the deal will support growth and job creation in Albuquerque as the firm looks to expand capabilities in the nuclear supply chain.
-
EQT Private Equity and Goldman Sachs Asset Management Acquire Parexel from Pamplona Capital Management
July 2, 2021
Healthcare Services
EQT Private Equity (EQT IX) and Goldman Sachs Asset Management's Private Equity business have agreed to acquire Parexel from Pamplona Capital Management for an enterprise value of USD 8.5 billion. Parexel, a global clinical research organization co-headquartered in Durham, North Carolina and Newton, Massachusetts, employs more than 17,000 people and provides outsourced clinical development, regulatory, market access and consulting services to the pharma and biotech industry.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.